The SUSTAIN 9 double-blind, parallel-group trial enrolled adults with T2DM and aimed to investigate the efficacy and safety of semaglutide when added to SGLT2 inhibitor therapy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.